Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Next Previous
Trial Profile

Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tivanisiran (Primary)
  • Indications Dry eyes; Ocular pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sylentis

Most Recent Events

  • 14 Mar 2016 Results and additional analysis of this clinical trial will be presented at the ARVO conference in May 2016, according to a Sylentis media release.
  • 14 Mar 2016 Results published in a Sylentis media release.
  • 22 May 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top